Phase I Study of Concomitant Chemoradiotherapy with Irinotecan, 5‐FU., and Hydroxyurea for Patients with Advanced and/or Recurrent Head and Neck Cancer

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer Journal

• Publication date

  2005-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00130404-200503000-00009PMID 15969989
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

  2004cited by this paper
• Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.

  2004cited by this paper
• Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer

  2003cited by this paper
• Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.

  2003cited by this paper
• Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review.

  2003cited by this paper
• The role of radiation therapy in preventing regional recurrences of invasive squamous cell carcinoma of the vulva.

  2003cited by this paper
• Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

  2003cited by this paper
• Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.

  2003cited by this paper
• Long-term outcome of re-irradiation with concomitant chemotherapy for locally recurrent squamous cell carcinoma of the head and neck

  2003cited by this paper
• The camptothecins.

  2003cited by this paper
• Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.

  2003cited by this paper
• Cancer Statistics, 2003

  2003cited by this paper
• Head and neck cancer.

  2001cited by this paper
• Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.

  2001cited by this paper
• Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer.

  2001cited by this paper
• RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck.

  2001cited by this paper
• Topoisomerase I inhibitors in the treatment of head and neck cancer.

  2001cited by this paper
• Mature results of a Phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with Stage III and IV squamous cell carcinoma of the head and neck

  2000cited by this paper
• Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.

  2000cited by this paper
• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

  2000cited by this paper
• Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study.

  1999cited by this paper
• Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.

  1999cited by this paper
• Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.

  1999cited by this paper
• Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients.

  1998cited by this paper
• Combined Surgery and Radiation Therapy for Squamous Cell Carcinoma of the Hypopharynx

  1997cited by this paper
• Combined surgery and radiation therapy for squamous cell carcinoma of the hypopharynx.

  1997cited by this paper
• Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease.

  1995cited by this paper
• Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells.

  1992cited by this paper
• Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I.

  1992cited by this paper
• Head and neck cancer.

  1991cited by this paper
• Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I.

  1989cited by this paper

• Unconventional EGF-induced ERK1/2-mediated Kv1.3 endocytosis

  2016cites this paper
• A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.

  2013cites this paper
• Hydroxyurea: a key player in cancer chemotherapy

  2012cites this paper
• Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation

  2011cites this paper
• Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications.

  2011cites this paper
• Angiogenesis in Head and Neck Cancer: A Review of the Literature

  2011cites this paper
• Chemoreirradiation for recurrent salivary gland malignancies.

  2010cites this paper
• Reirradiation with Alternating Docetaxel-Based Chemotherapy for Recurrent Head and Neck Squamous Cell Carcinoma

  2010cites this paper
• Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue

  2010cites this paper
• Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.

  2008cites this paper
• Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.

  2006cites this paper